Session » Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0457

A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis

1:00PM-3:00PM: Abstract Number: 0454

Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients

1:00PM-3:00PM: Abstract Number: 0448

All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study

1:00PM-3:00PM: Abstract Number: 0456

Application of Adult ACR/EULAR 2022 Classification Criteria in Pediatric Vasculitis Patients

1:00PM-3:00PM: Abstract Number: 0445

Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis

1:00PM-3:00PM: Abstract Number: 0438

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies

1:00PM-3:00PM: Abstract Number: 0436

Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 0439

Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles

1:00PM-3:00PM: Abstract Number: 0433

Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset

1:00PM-3:00PM: Abstract Number: 0440

COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience

1:00PM-3:00PM: Abstract Number: 0452

Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden

1:00PM-3:00PM: Abstract Number: 0449

Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis

1:00PM-3:00PM: Abstract Number: 0451

Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study

1:00PM-3:00PM: Abstract Number: 0450

Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 0442

Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey

1:00PM-3:00PM: Abstract Number: 0447

Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample

1:00PM-3:00PM: Abstract Number: 0435

Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes

1:00PM-3:00PM: Abstract Number: 0437

Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study

1:00PM-3:00PM: Abstract Number: 0441

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort

1:00PM-3:00PM: Abstract Number: 0455

Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients

1:00PM-3:00PM: Abstract Number: 0432

Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort

1:00PM-3:00PM: Abstract Number: 0444

Prevalence of Frailty and Associated Factors in Patients with Vasculitis

1:00PM-3:00PM: Abstract Number: 0443

Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis

1:00PM-3:00PM: Abstract Number: 0434

Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample

1:00PM-3:00PM: Abstract Number: 0446

The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis

1:00PM-3:00PM: Abstract Number: 0453

Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].